Tailored therapy for early breast cancer using tumor DNA test
Part of Cancer, Skin clinical trials.
This trial tests whether some people with early-stage, hormone-positive breast cancer can safely skip chemotherapy and instead receive a targeted pill (ribociclib) with hormone therapy. A special blood test looks for tiny pieces of tumor DNA to help guide treatment decisions.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are a woman aged 18 to 70.
- You have had surgery to remove your breast cancer, and the tumor was completely removed.
- Your cancer is hormone-receptor positive (feeds on hormones) and HER2-negative (a specific protein marker).
- You have certain tumor features (like size, lymph node involvement, or grade) as specified by the study.
- Your blood test after surgery shows no leftover tumor DNA (ctDNA-negative).
- You are generally healthy (able to do daily activities) and have adequate organ function.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether adding a targeted pill (dalpiciclib) to standard hormone therapy can safely replace chemotherapy for women with small, hormone-positive, high-risk breast cancers.
This trial tests adding ribociclib (a targeted pill) to standard hormone therapy for people with early but high-risk HR-positive, HER2-negative breast cancer, after surgery.
This Phase 2 study tests a “precision platform” approach—treatment before surgery—based on specific test results from your breast tumor. It may help determine whether the treatment plan works better for people with particular breast cancer subtypes and healthy organ function.
This trial tests whether some people with hormone receptor-positive, HER2-negative early breast cancer can safely receive less chemotherapy when also taking the targeted drug ribociclib after surgery. You may qualify if you have a specific stage of breast cancer and are planning to take hormone therapy for at least 5 years.
This trial tests ribociclib, a targeted therapy, for women with hormone receptor-positive, HER2-negative breast cancer who still have cancer cells in the breast or lymph nodes after initial chemotherapy. It aims to reduce the chance of cancer coming back.
This trial tests whether adding a targeted therapy (a CDK4/6 inhibitor) to standard hormone therapy can let some people safely skip chemotherapy. It is for early-stage, hormone-positive breast cancer that is also HER2-positive, and aims to reduce side effects while keeping the cancer from coming back.
Hear when a new Breast cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.